Sicart Associates’s CG Oncology CGON Stock Holding History

Sicart Associates’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.5M	Hold	25,000	–	–	0.36%	42
2026 Q2	$1.78M	Hold	25,000	–	–	0.43%	41
2026 Q1	$1.69M	Hold	25,000	–	–	0.43%	42
2025 Q4	$1.04M	Hold	25,000	–	–	0.28%	45
2025 Q3	$1.01M	Hold	25,000	–	–	0.27%	45
2025 Q2	$650K	Hold	25,000	–	–	0.23%	45
2025 Q1	$612K	Hold	25,000	–	–	0.21%	46
2024 Q4	$717K	Hold	25,000	–	–	0.26%	46
2024 Q3	$943K	Hold	25,000	–	–	0.33%	45
2024 Q2	$789K	Hold	25,000	–	–	0.3%	46
2024 Q1	$1.1M	Buy	+25,000	New	+$1.02M	0.4%	46

Other funds holding CGON

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sicart Associates's CGON Position: Q3 2026 in Review

Sicart Associates held its CG Oncology (CGON) position steady in Q3 2026 at 25,000 shares worth $1.5M. The position accounts for 0.36% of the portfolio, ranked #42.

Sicart Associates first reported a position in CGON in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.78M in Q2 2026. 103 funds tracked by Wall St. Rank hold CGON as of Q3 2026.

Sicart Associates held 25,000 shares of CG Oncology worth $1.5M as of Q3 2026.
Sicart Associates left its CG Oncology share count unchanged in Q3 2026.
CG Oncology made up 0.36% of Sicart Associates's portfolio in Q3 2026, its #42 holding.
Sicart Associates first reported a position in CG Oncology in Q1 2024 and has held it in 11 quarters since.
Sicart Associates's CG Oncology position peaked at $1.78M in Q2 2026.
103 funds tracked by Wall St. Rank held CG Oncology as of Q3 2026.

Based on Sicart Associates's 13F filing for Q3 2026, filed 29 Oct 2026.